QuantumDX. Malaria DNA assay, Covid Sars-Cov2 test
Performance of the QPLEX™ Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition Background: Alzheimer’s disease (AD) is an irreversible neurodegenerative disease characterized by the hallmark finding of cerebral amyloid deposition. Many researchers have tried to predict the existence of cerebral amyloid deposition by using easily accessible blood plasma samples, but the effectiveness of such strategies… Continue reading
Evaluation of ” Caterina assay“: An Alternative Tool to the Commercialized Kits Used for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Identification Here we describe the first molecular test developed in the early stage of the pandemic to diagnose the first cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Sardinian patients in February-March 2020, when diagnostic… Continue reading
Determining the Need for Repeat Testing of Blood Ethanol Concentration: Evaluation of the Synchron Blood Ethyl Alcohol Assay Kit. In clinical laboratories, a common practice used to verify tests prior to reporting is repeat testing. Our objective was to evaluate the differences between the results of blood ethanol concentration (BEC) test repetitions and report on the… Continue reading
Developmental validation of the Huaxia™ Platinum PCR amplification package: A 6-dye multiplex direct amplification assay designed for Chinese language reference samples. The Huaxia™ Platinum Package for brief tandem repeat (STR) amplification was designed to satisfy the wants of the quickly rising Chinese language forensic database. This PCR multiplex permits simultaneous amplification of the next autosomal loci: D3S1358, vWA,… Continue reading
The FP7 European Union funded NANOMAL PROJECT is developing a simple, rapid and affordable point-of-care (POC) handheld diagnostic device to confirm The device should provide the same quality of result as a referral laboratory, fraction of the time and cost. Each device could cost about the price of a smart phone initially, may be issued… Continue reading
Anti-malarial interventions. In addition to improving immediate patient outcomes, the project will allow the researchers to build a better picture of levels of drug resistance in stricken areas. It will also give them information on population impacts of anti-malarial interventions. Clinical trials of the device are expected to begin within three years, after which it… Continue reading
The !5.2million (£4million) Nanomal project – launched today – is planning to provide an affordable hand-held diagnostic device to swiftly detect malaria infection and parasites’ drug resistance. It was set up in response to increasing signs that the malaria parasite is mutating to resist the most powerful class of anti-malaria drugs, artemisinins. The European Commission… Continue reading
It will allow healthcare workers in remote rural areas to deliver effective drug treatments to counter resistance more quickly, potentially saving lives. Optimising individual treatments for patients (personalizing treatment) Assessing the epidemiology of drug resistance in malaria endemic areas(identifying emerging drug resistance in real-time) Assessing population impacts of anti-malarial interventions
The device – the size and shape of a mobile phone – will use a range of latest proven nanotechnologies to rapidly analyse the parasite DNA from a blood sample. It will then provide a malaria diagnosis and comprehensive screening for drug susceptibility in less than 20 minutes, while the patient waits. With immediately available… Continue reading